Radiotherapy for Hodgkin’s Disease

  • Chung K. K. Lee
Part of the Medical Radiology book series (MEDRAD)


Clin Oncol Radiat Oncol Biol Phys Posterior Field Mediastinal Disease Staging Laparotomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agnarsson BA, Kadin ME (1989) The immunophenotype of Reed-Sternberg cells: a study of 50 cases of Hodgkin’s disease using fixed frozen tissues. Cancer 63:2083–2087PubMedGoogle Scholar
  2. Anonymous (1993) The Ann Arbor Staging Classifications. CA: A Cancer Journal for Clinicians 43:333Google Scholar
  3. Aragon de la Cruz G, Cardenes H, Otero J et al (1989) Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin’s disease. Cancer 63:1799–1803PubMedGoogle Scholar
  4. Birdwell SH, Hancock SL, Varghese A et al (1995) Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 37:67–73Google Scholar
  5. Biti Ga, Cimino G, Cartoni C et al (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–II A Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378–382PubMedGoogle Scholar
  6. Bonadonna G (1994) Modern treatment of malignant lymphomas: a multi-disciplinary approach? Ann Oncol 5[Suppl 2]:5–16PubMedGoogle Scholar
  7. Bonfante V, Viviani S, Devizz IL et al (2001) Ten years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved-field (IFRT) in early stage Hodgkin’s disease (abstract). Proceedings of ASCO 281aGoogle Scholar
  8. Brada M, Easton D, Horwich A et al (1986) Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin’s disease. Radiother Oncol 5:15–22PubMedGoogle Scholar
  9. Carbone PP, Kaplan HS, Musshoff K et al (1971) Report of the committee on Hodgkin’s staging classification. Cancer Res 31:1860PubMedGoogle Scholar
  10. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease. An analysis of technique, tumor eradication and complications. Cancer 37:2813–2825PubMedGoogle Scholar
  11. Carmel RJ, Palos BB, Duggan JP et al (1976) Testicular shielding of patients receiving inverted-Y irradiation. Int J Radiat Oncol Biol Phys 1[Suppl 11]:61Google Scholar
  12. Castellino RA, Hoppe RT, Blank N et al (1984) Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin’s disease. Am J Radiol 143:37–41Google Scholar
  13. Castellino RA, Blank N, Hoppe RT et al (1986) Hodgkin’s disease: contributions of chest CT in the initial staging evaluation. Radiology 160:603–605PubMedGoogle Scholar
  14. Coia LR, Hanks GE (1988) Complications from large field intermediate dose infradiaphragmatic radiation: an analysis of the Patterns of Care Outcomes Studies for Hodgkin’s disease and seminoma. Int J Radiat Oncol Biol Phys 15:29–35PubMedGoogle Scholar
  15. Cosset JM, Henry-Amar M, Meerwaldt JH et al (1992) The E.O.R.T.C. trials for limited stage Hodgkin’s disease. Eur J Cancer 11:1847–1850Google Scholar
  16. Cosset JM, Henry-Amar M, Meerwaldt JH (1991) Long-term toxicity of early stages of Hodgkin’s disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2:77–82PubMedGoogle Scholar
  17. Crnkovich MJ, Leopold K, Hoppe RT et al (1987) Stage I to IIB Hodgkin’s disease: the combined experience at Stanford and the Joint Center for Radiation Therapy. J Clin Oncol 5:1041–1049PubMedGoogle Scholar
  18. De Vita VT, Hellman J, Rosenberg SA et al (2005) Cancer principles and practice of oncology, 7th edn. Williams and Wilkins, LippincottGoogle Scholar
  19. De Wit M, Bohuslavizki KH, Buchert R et al (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12:29–37PubMedGoogle Scholar
  20. Diehl V, Loeffler M, Pfreundschuh M et al (1995) Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycle of alternating chemotherapy in patients with advanced Hodgkin’s disease. Ann Oncol 6:901–910PubMedGoogle Scholar
  21. Doggett Rs, Colby TV, Dorfman RF (1983) Interfollicular Hodgkin’s disease. Am J Surg Pathol 7:145–149PubMedGoogle Scholar
  22. Donaldson SS, Link MP (1987) Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease. J Clin Oncol 5:742–749PubMedGoogle Scholar
  23. Duehmke E, Diehl V, Loeffler M et al (1995) Randomized trial with early stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone (abstract). Int J Radiat Oncol Biol Phys 32[Suppl 1]:213Google Scholar
  24. Engert A, Schiller P, Pfistner B et al (2001) Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients with intermediate-stage HD (abstract). Blood 98:768aGoogle Scholar
  25. Fabian CJ, Mansfield CM, Dahlberg S et al (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin Disease. Ann Intern Med 120:903–912PubMedGoogle Scholar
  26. Fletcher GH, Shukovsky LJ (1975) The interplay of radio-curability and tolerance in the irradiation of human cancers. J Radiol Electro 56:383–400Google Scholar
  27. Fraass B, Tepper J, Glatstein E, van de Geijn J (1983) Clinical use of matchline wedge for adjacent megavoltage radiation field matching. Int J Radiat Oncol Biol Phys 9:209PubMedGoogle Scholar
  28. Friedman S, Henry-Amar M, Casset JM et al (1988) Evolution of erythrocyte sedimentation rate as predictor of early relapse in post-therapy early-stage Hodgkin’s disease. J Clin Oncol 6:596PubMedGoogle Scholar
  29. Front D, Israel O (1995) The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 25:60–71PubMedGoogle Scholar
  30. Fuller L, Hagemeister F, North L et al (1988) The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin’s disease: preliminary results. Int J Radiat Oncol Biol Phys 14:683–692PubMedGoogle Scholar
  31. Gilbert R (1939) Radiotherapy in Hodgkin’s disease (malignant granulomatosis). Am J Roentgenol 41:198–241Google Scholar
  32. Grant L, Jackson W (1973) An investigation of the mantle technique. Clin Radiol 24:254–262PubMedGoogle Scholar
  33. Hancock SL, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242PubMedGoogle Scholar
  34. Hancock SL, Tucker MA, Hoppe RT (1993a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31PubMedGoogle Scholar
  35. Hancock SL, Tucker MA, Hoppe RT (1993b) Factors affecting late mortality from heart disease after treatment of Hodkin’s disease. JAMA 270:1949–1955PubMedGoogle Scholar
  36. Hanks GE, Kinzie JJ, White RL et al (1983) Patterns of care outcome studies: results of the national practice in Hodgkin’s disease. Cancer 51:569–573PubMedGoogle Scholar
  37. Haybittle J, Easterling M, Bennett M et al (1985) Review of British National Lymphoma Investigation studies of Hodgkin’s disease and development of prognostic index. Lancet 1:967–972PubMedGoogle Scholar
  38. Henry-Amar M, Friedman S, Hayat M et al (1991) Erythrocyte sedimentation rate predicts early survival in early-stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 114:361–365PubMedGoogle Scholar
  39. Hoppe RT (1990–1991) Hodgkin’s disease. Patterns of care study newsletter no 3. American College of Radiology, PhiladelphiaGoogle Scholar
  40. Hoppe RT, Rosenberg SA, Kaplan HS, Cox RS (1980) Prognostic factors in pathological stage IIIA Hodgkin’s diseases. Cancer 46:1240–1246PubMedGoogle Scholar
  41. Hoppe RT, Coleman CN, Cox RS et al (1982a) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 59:455–465PubMedGoogle Scholar
  42. Hoppe RT, Cox RS, Rosenberg SA et al (1982b) Prognostic factors in pathologic stage III Hodgkin’s disease. Cancer Treat Rep 66:743–749PubMedGoogle Scholar
  43. Horning SJ, Hoppe RT, Hancock SL et al (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822–1831PubMedGoogle Scholar
  44. Hueltenschmidt B, Sautter-Bihl ML, Lang O et al (2001) Whole body positron emission tomography in the treat of Hodgkin disease. Cancer 91:302–310PubMedGoogle Scholar
  45. Johnson RE, Ruhl U, Johnson SK, Glover M (1976) Split-course radiotherapy of Hodgkin’s disease. Local tumor control and normal tissue reactions. Cancer 37:1713–1717PubMedGoogle Scholar
  46. Kaplan HS (1962) The radical radiotherapy of regionally localized Hodgkin’s disease. Radiology 89:553–561Google Scholar
  47. Kaplan HS (1966) Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin’s disease. Cancer Res 26:1221–1224PubMedGoogle Scholar
  48. Kaplan HS (1980) Hodgkin’s disease, 2nd edn. Harvard University Press, Cambridge, MAGoogle Scholar
  49. Karmiris TD, Grigoriou E, Tsantekidou M et al (2003) Treatment of early clinically staged Hodgkin’s disease with a combination of ABVD chemotherapy plus limited field radiotherapy. Leuk Lymph 44:1523–1528Google Scholar
  50. Khan FM (1994) The physics of radiation therapy, 2nd edn. William and Wilkins, BaltimoreGoogle Scholar
  51. Kinzie JJ, Hanks GE, Maclean GJ et al (1983) Patterns of care study: Hodgkin’s disease relapse rates and adequacy of portals. Cancer 52:2223–2226PubMedGoogle Scholar
  52. Laskar S, Gupta T, Vimal S et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22:62–68PubMedGoogle Scholar
  53. Lee CKK, Bloomfield CD, Levitt SH (1979) Prophylactic whole lung irradiation for extensive mediastinal Hodgkin’s disease. Proc Am Soc Clin Oncol 20:4411Google Scholar
  54. Lee CK, Bloomfield CD, Goldman AJ et al (1980) Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiotherapy. Cancer 46:2403–2409PubMedGoogle Scholar
  55. Lee CK, Bloomfield CD, Goldman A et al (1984) Liver irradiation in stage IIIA Hodgkin’s disease patients with splenic involvement. Am J Clin Oncol 7:149–157PubMedGoogle Scholar
  56. Lee CK, Aeppli DM, Bloomfield CD et al (1990) Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin’s disease. An evaluation of the gains achieved with radical radiotherapy. Int J Radiat Oncol Biol Phys 19:547–549PubMedGoogle Scholar
  57. LeFloch O, Donaldson SS, Kaplan HS (1976) Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkin’s disease. Cancer 38:2263–2268Google Scholar
  58. Leibenhaut MH, Hoppe R, Efron B et al (1989) Prognostic indicators of laparotomy findings in clinical stage I–II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7:81–91PubMedGoogle Scholar
  59. Leopold KA, Canellos GP, Rosenthal D et al (1989) Stage IA-IIB Hodgkin’s disease: Staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 7:1059–1065PubMedGoogle Scholar
  60. Lister TA, Crowther D, Sutcliffe S et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Coswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  61. Longo DL, Young RC, Wesley M et al (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4:1295–1306PubMedGoogle Scholar
  62. Lukes R (1971) Criteria for involvement of lymph node, bone marrow, spleen, and liver in Hodgkin’s disease. Cacer Res 31:1755Google Scholar
  63. Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26:1063–1081PubMedGoogle Scholar
  64. Lutz W, Larsen R (1983) Technique to match mantle and paraaortic fields. Int J Radiat Oncol Biol Phys 9:1753PubMedGoogle Scholar
  65. Madelli F, Anselmo A, Cartoni C et al (1986) Evaluation of therapeutic modalities in the control of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 12:1617–1620Google Scholar
  66. Mai DHW, Peschel RE, Portlock D et al (1991) Stage I and II subdiaphragmatic Hodgkin’s disease. Cancer 68:1467–1481Google Scholar
  67. Mason D, Banks P, Chan J et al (1994) Nodular lymphocyte predominance Hodgkin’s disease: a distinct clinicopathologic entity. Am J Surg Pathol 18:526–530PubMedGoogle Scholar
  68. Mauch PM (1994) Controversies in the management of early stage Hodgkin’s disease. Blood 2:318–329Google Scholar
  69. Mauch P, Greenberg J, Lewin A et al (1983) Prognostic factors in patients with subdiaphragmatic Hodgkin’s disease. Hematol Oncol 1:205–214PubMedGoogle Scholar
  70. Mauch P, Tarbell N, Weinstein H et al (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease. Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576–1583PubMedGoogle Scholar
  71. Mauch P, Larson D, Osteen R et al (1990) Prognostic factors positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8:257–265PubMedGoogle Scholar
  72. Mauch P, Kalish L, Kadin M et al (1993) Patterns of presentation of Hodgkin’s disease. Cancer 71:2062–2071PubMedGoogle Scholar
  73. Mauch P, Canellos G, Shulman L et al (1995a) Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin’s disease: preliminary results of a prospective trial. J Clin Oncol 13:947–952PubMedGoogle Scholar
  74. Mauch P, Kalish LA, Marchus KC et al (1995b) Long-term survival in Hodgkin’s disease: relative impact of mortality, second tumors infection, and cardiovascular disease. Cancer J Sci Am 1:33–42PubMedGoogle Scholar
  75. Miller RW, van de Geijn J, Raubitschek AA et al (1995) Dosimetric considerations in treating mediastinal disease with mantle fields: characterization of the dose under mantle blocks. Int J Radiat Oncol Biol Phys 32:1083–1095PubMedGoogle Scholar
  76. Molrine D, George S, Tarbell N et al (1995) Antibody responses to polysaccharide-conjugate vaccines following treatment for Hodgkin’s disease. Ann Intern Med 123:824–828Google Scholar
  77. Myrianthopoulos L, Nautiyal J, Powers C et al (1995) A re-evaluation of dose response in Hodgkin’s disease (abstract). Radiology 197:359Google Scholar
  78. Nag AK, Li S, Neuberg D et al (2004) Factors influencing treatment recommendations in early-stage Hodgkin’s disease: a survey of physicians. Ann Oncol 15:261–269Google Scholar
  79. Neiman RR, Rosen PJ, Lukes RJ (1973) Lymphocyte-depletion Hodgkin’s disease. N Engl J Med 288:751–755PubMedGoogle Scholar
  80. Ng AK, Li S, Neuberg D et al (2004) Factors influencing treatment recommendations in early-stage Hodgkin’s disease: a survey of physicians. Ann Oncol 15:261–269PubMedGoogle Scholar
  81. Noordijk EM, Carde P, Mandard AM et al (1994) Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin’s disease. Ann Oncol 5[Suppl 2]: S107–S112Google Scholar
  82. Oberlin O, Leverger G, Pacquement H et al (1992) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 10:1602–1608PubMedGoogle Scholar
  83. Page V, Gardner A, Karzmark CJ (1970) Physical and dosimetric aspects of the radiotherapy of malignant lymphomas. I. The mantle technique. Radiology 96:609–626PubMedGoogle Scholar
  84. Palos B, Kaplan HS, Karzmark CJ (1971) The use of thin lung shields to deliver limited whole-lung irradiation during mantle-field treatment of Hodgkin’s disease. Radiology 101:441–442PubMedGoogle Scholar
  85. Pavlovsky S, Maschio M, Santarelli MT et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473PubMedGoogle Scholar
  86. Peters M (1950) A study of survival in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311Google Scholar
  87. Peters MV (1966) Prophylactic treatment of adjacent areas in Hodgkin’s disease. Cancer Res 26:1232–1243PubMedGoogle Scholar
  88. Prosnitz LR (1990) Hodgkin’s disease: the right dose. Int J Radiat Oncol Biol Phys 19:803–804PubMedGoogle Scholar
  89. Raemakers J, Burgers M, Henry-Amar et al (1997) Patients with stage III/IV Hodkin’s disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 8[Suppl 1]:111–114Google Scholar
  90. Ray GR, Wolf PH, Kaplan HS (1973) Value of laboratory indicators in Hodgkin’s disease: Preliminary results. NCI Monogr 36:315Google Scholar
  91. Rosenberg SA, Kaplan HS (1966) Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res 26:1225–1231PubMedGoogle Scholar
  92. Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease: 1962–1984. Int J Radiat Oncol Biol Phys 11:5–22PubMedGoogle Scholar
  93. Rostock RA, Siegelman SS, Lenhard RE et al (1983) Thoracic CT scanning for mediastinal Hodgkin’s disease. Results and therapeutic implications. Int J Radiat Oncol Biol Phys 9:1451–1457PubMedGoogle Scholar
  94. Rutherford C, Desforges J, Davies B et al (1980) The decision to perform staging laparotomy in symptomatic Hodgkin’s disease. Br J Haematol 44:347–358PubMedGoogle Scholar
  95. Schellong G, Brämswig JH, Schwarze EW et al (1988) An approach to reduce treatment and invasive strategy in childhood Hodgkin’s disease. The sequence of the German DAL multi-center studies. Bull Cancer 75:41–51PubMedGoogle Scholar
  96. Schellong G, Brämswig JH, Hörnig-Franz I et al (1994) Hodgkin’s disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Ann Oncol 5[Suppl 2]:113–155PubMedGoogle Scholar
  97. Schewe KL, Kun L, Cox J (1989) A step toward ending the controversies in Hodgkin’s disease. Int J Radiat Oncol Biol Phys 17:1123–1124PubMedGoogle Scholar
  98. Schoder H, Meta J, Yap C et al (2001) Effect of whole-body (18F)FDG-PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42:1139–1143PubMedGoogle Scholar
  99. Siber G, Gorham C, Martin P et al (1986) Antibody response to pretreatment immunization and posttreatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin’s disease. Ann Intern Med 104:467–475PubMedGoogle Scholar
  100. Somers R, Tubiana M, Henry-Amar M (1989) EORTC Lymphoma Cooperative Group Studies in clinical stage I–II Hodgkin’s disease 1963–1987. Rec Res Cancer Res 117:175–181Google Scholar
  101. Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphom: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419PubMedGoogle Scholar
  102. Specht L, Nissen NI (1988) Hodgkin’s disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavorable combination. Eur J Haematol 40:396–402PubMedGoogle Scholar
  103. Specht L, Gray RG, Clarke MJ et al (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16:830–843PubMedGoogle Scholar
  104. Sutcliff S, Gospodarowicz, Bergsagel D et al (1985) Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol 3:393–401Google Scholar
  105. Taylor M, Kaplan H, Nelson T (1985) Staging laparotomy with splenectomy for Hodgkin’s disease: the Stanford experience. World J Surg 9:449–460PubMedGoogle Scholar
  106. Tubiana M, Henry-Amar M, Hayat M et al (1982) Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 54:95–104Google Scholar
  107. Tubiana M, Henry-Amar M, Burgers MV et al (1984) Prognostic significance of erythrocyte sedimentation rate in clinical stages I–II of Hodgkin’s disease. J Clin Oncol 2:194PubMedGoogle Scholar
  108. Tubiana M, Henry-Amar M, Carde P et al (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73:47–56PubMedGoogle Scholar
  109. Van der Velden JW, van Putten WLJ, Guinee VF et al (1988) Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin’s disease. Int J Cancer 42:252–255PubMedGoogle Scholar
  110. Van Leeuwen FD, Klokman WJ, Stovall M et al (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87:1530–1537PubMedGoogle Scholar
  111. Vijayakumar S, Myrianthopolos LC (1992) An updated dose-response analysis of Hodgkin’s disease. Radiother Oncol 24:1–13PubMedGoogle Scholar
  112. Vijayakumar S, Rosenberg I, Brandt T et al (1989) The effect of posterior midline spinal corde block (PMSB) on Hodgkin’s disease therapeutic dose estimates: a dosimetric study (abstract). Int J Radiat Oncol Biol Phys 17:170Google Scholar
  113. Weisenberger TH, Juillard GJF (1977) Upper extremity lymphangiography in the radiation therapy of lymphomas and carcinoma of the breast. Radiology 122:227–230Google Scholar
  114. Zittoun R, Audebert A, Hoerni B et al (1985) Extended field versus involved field irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207–214PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Chung K. K. Lee
    • 1
  1. 1.University of Minnesota Medical School, MMC494MinneapolisUSA

Personalised recommendations